Vir Biotechnology (VIR) Competitors

Vir Biotechnology logo
$9.58 -0.38 (-3.82%)
Closing price 04:00 PM Eastern
Extended Trading
$9.58 0.00 (0.00%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

VIR vs. PRAX, CYTK, ABVX, ALKS, and RYTM

Should you buy Vir Biotechnology stock or one of its competitors? Vir Biotechnology's main competitors and comparable companies include Praxis Precision Medicines (PRAX), Cytokinetics (CYTK), Abivax (ABVX), Alkermes (ALKS), and Rhythm Pharmaceuticals (RYTM). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Vir Biotechnology compare to Praxis Precision Medicines?

Praxis Precision Medicines (NASDAQ:PRAX) and Vir Biotechnology (NASDAQ:VIR) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

In the previous week, Praxis Precision Medicines had 1 more articles in the media than Vir Biotechnology. MarketBeat recorded 34 mentions for Praxis Precision Medicines and 33 mentions for Vir Biotechnology. Praxis Precision Medicines' average media sentiment score of 0.66 beat Vir Biotechnology's score of 0.60 indicating that Praxis Precision Medicines is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Praxis Precision Medicines
8 Very Positive mention(s)
6 Positive mention(s)
11 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Positive
Vir Biotechnology
4 Very Positive mention(s)
6 Positive mention(s)
13 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Praxis Precision Medicines has a beta of 2.85, meaning that its stock price is 185% more volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

Praxis Precision Medicines presently has a consensus target price of $647.68, suggesting a potential upside of 108.75%. Vir Biotechnology has a consensus target price of $22.57, suggesting a potential upside of 135.61%. Given Vir Biotechnology's higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Praxis Precision Medicines.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Praxis Precision Medicines
2 Sell rating(s)
1 Hold rating(s)
16 Buy rating(s)
3 Strong Buy rating(s)
2.91
Vir Biotechnology
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

Praxis Precision Medicines has higher earnings, but lower revenue than Vir Biotechnology. Praxis Precision Medicines is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Praxis Precision Medicines$8.55M1,014.27-$303.27M-$12.80N/A
Vir Biotechnology$68.56M23.93-$437.99M-$1.26N/A

67.8% of Praxis Precision Medicines shares are held by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are held by institutional investors. 3.0% of Praxis Precision Medicines shares are held by insiders. Comparatively, 2.9% of Vir Biotechnology shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Vir Biotechnology's return on equity of -21.38% beat Praxis Precision Medicines' return on equity.

Company Net Margins Return on Equity Return on Assets
Praxis Precision MedicinesN/A -29.41% -28.19%
Vir Biotechnology N/A -21.38%-16.97%

Summary

Praxis Precision Medicines beats Vir Biotechnology on 10 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Cytokinetics?

Vir Biotechnology (NASDAQ:VIR) and Cytokinetics (NASDAQ:CYTK) are both mid-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, institutional ownership, risk, valuation, earnings, profitability, media sentiment and analyst recommendations.

Vir Biotechnology presently has a consensus target price of $22.57, indicating a potential upside of 135.61%. Cytokinetics has a consensus target price of $106.67, indicating a potential upside of 100.61%. Given Vir Biotechnology's higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than Cytokinetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vir Biotechnology
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Cytokinetics
1 Sell rating(s)
1 Hold rating(s)
19 Buy rating(s)
0 Strong Buy rating(s)
2.86

Vir Biotechnology has a beta of 1.7, indicating that its share price is 70% more volatile than the broader market. Comparatively, Cytokinetics has a beta of 0.45, indicating that its share price is 55% less volatile than the broader market.

65.3% of Vir Biotechnology shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by insiders. Comparatively, 2.6% of Cytokinetics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Vir Biotechnology has higher earnings, but lower revenue than Cytokinetics. Cytokinetics is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$68.56M23.93-$437.99M-$1.26N/A
Cytokinetics$88.04M84.13-$784.96M-$6.04N/A

Vir Biotechnology has a net margin of 0.00% compared to Cytokinetics' net margin of -686.63%. Cytokinetics' return on equity of 0.00% beat Vir Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
Vir BiotechnologyN/A -21.38% -16.97%
Cytokinetics -686.63%N/A -48.26%

In the previous week, Vir Biotechnology had 20 more articles in the media than Cytokinetics. MarketBeat recorded 33 mentions for Vir Biotechnology and 13 mentions for Cytokinetics. Vir Biotechnology's average media sentiment score of 0.60 beat Cytokinetics' score of 0.60 indicating that Vir Biotechnology is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vir Biotechnology
4 Very Positive mention(s)
6 Positive mention(s)
13 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Cytokinetics
5 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
2 Very Negative mention(s)
Positive

Summary

Vir Biotechnology beats Cytokinetics on 12 of the 17 factors compared between the two stocks.

How does Vir Biotechnology compare to Abivax?

Vir Biotechnology (NASDAQ:VIR) and Abivax (NASDAQ:ABVX) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, media sentiment, profitability, earnings, valuation, dividends and analyst recommendations.

Vir Biotechnology currently has a consensus price target of $22.57, indicating a potential upside of 135.61%. Abivax has a consensus price target of $155.00, indicating a potential upside of 85.38%. Given Vir Biotechnology's higher probable upside, equities analysts clearly believe Vir Biotechnology is more favorable than Abivax.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vir Biotechnology
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Abivax
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.88

Vir Biotechnology's return on equity of -21.38% beat Abivax's return on equity.

Company Net Margins Return on Equity Return on Assets
Vir BiotechnologyN/A -21.38% -16.97%
Abivax N/A -91.69%-71.96%

In the previous week, Vir Biotechnology had 28 more articles in the media than Abivax. MarketBeat recorded 33 mentions for Vir Biotechnology and 5 mentions for Abivax. Abivax's average media sentiment score of 1.13 beat Vir Biotechnology's score of 0.60 indicating that Abivax is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vir Biotechnology
4 Very Positive mention(s)
6 Positive mention(s)
13 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Abivax
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vir Biotechnology has a beta of 1.7, suggesting that its stock price is 70% more volatile than the broader market. Comparatively, Abivax has a beta of 1.36, suggesting that its stock price is 36% more volatile than the broader market.

Abivax has lower revenue, but higher earnings than Vir Biotechnology. Abivax is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$68.56M23.93-$437.99M-$1.26N/A
AbivaxN/AN/A-$380.27M-$6.06N/A

65.3% of Vir Biotechnology shares are owned by institutional investors. Comparatively, 47.9% of Abivax shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Vir Biotechnology beats Abivax on 10 of the 14 factors compared between the two stocks.

How does Vir Biotechnology compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Vir Biotechnology (NASDAQ:VIR) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Alkermes has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market. Comparatively, Vir Biotechnology has a beta of 1.7, meaning that its stock price is 70% more volatile than the broader market.

In the previous week, Vir Biotechnology had 16 more articles in the media than Alkermes. MarketBeat recorded 33 mentions for Vir Biotechnology and 17 mentions for Alkermes. Alkermes' average media sentiment score of 0.85 beat Vir Biotechnology's score of 0.60 indicating that Alkermes is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Alkermes
2 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Vir Biotechnology
4 Very Positive mention(s)
6 Positive mention(s)
13 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Vir Biotechnology has a net margin of 0.00% compared to Alkermes' net margin of -0.02%. Alkermes' return on equity of 0.40% beat Vir Biotechnology's return on equity.

Company Net Margins Return on Equity Return on Assets
Alkermes-0.02% 0.40% 0.19%
Vir Biotechnology N/A -21.38%-16.97%

Alkermes has higher revenue and earnings than Vir Biotechnology. Alkermes is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Alkermes$1.48B5.29$241.66M-$0.02N/A
Vir Biotechnology$68.56M23.93-$437.99M-$1.26N/A

Alkermes currently has a consensus price target of $55.73, indicating a potential upside of 19.96%. Vir Biotechnology has a consensus price target of $22.57, indicating a potential upside of 135.61%. Given Vir Biotechnology's stronger consensus rating and higher probable upside, analysts plainly believe Vir Biotechnology is more favorable than Alkermes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alkermes
1 Sell rating(s)
5 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.65
Vir Biotechnology
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78

95.2% of Alkermes shares are owned by institutional investors. Comparatively, 65.3% of Vir Biotechnology shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 2.9% of Vir Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Alkermes beats Vir Biotechnology on 10 of the 16 factors compared between the two stocks.

How does Vir Biotechnology compare to Rhythm Pharmaceuticals?

Vir Biotechnology (NASDAQ:VIR) and Rhythm Pharmaceuticals (NASDAQ:RYTM) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, profitability, risk, media sentiment, valuation, earnings, institutional ownership and dividends.

Rhythm Pharmaceuticals has higher revenue and earnings than Vir Biotechnology. Rhythm Pharmaceuticals is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vir Biotechnology$68.56M23.93-$437.99M-$1.26N/A
Rhythm Pharmaceuticals$189.76M39.27-$196.54M-$2.90N/A

Vir Biotechnology currently has a consensus target price of $22.57, indicating a potential upside of 135.61%. Rhythm Pharmaceuticals has a consensus target price of $142.00, indicating a potential upside of 32.12%. Given Vir Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe Vir Biotechnology is more favorable than Rhythm Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vir Biotechnology
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
1 Strong Buy rating(s)
2.78
Rhythm Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
18 Buy rating(s)
0 Strong Buy rating(s)
2.77

In the previous week, Vir Biotechnology had 26 more articles in the media than Rhythm Pharmaceuticals. MarketBeat recorded 33 mentions for Vir Biotechnology and 7 mentions for Rhythm Pharmaceuticals. Rhythm Pharmaceuticals' average media sentiment score of 0.76 beat Vir Biotechnology's score of 0.60 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Vir Biotechnology
4 Very Positive mention(s)
6 Positive mention(s)
13 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Rhythm Pharmaceuticals
2 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Vir Biotechnology has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market. Comparatively, Rhythm Pharmaceuticals has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market.

65.3% of Vir Biotechnology shares are owned by institutional investors. 2.9% of Vir Biotechnology shares are owned by insiders. Comparatively, 5.9% of Rhythm Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vir Biotechnology has a net margin of 0.00% compared to Rhythm Pharmaceuticals' net margin of -69.03%. Vir Biotechnology's return on equity of -21.38% beat Rhythm Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Vir BiotechnologyN/A -21.38% -16.97%
Rhythm Pharmaceuticals -69.03%-171.16%-43.00%

Summary

Vir Biotechnology beats Rhythm Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

Get Vir Biotechnology News Delivered to You Automatically

Sign up to receive the latest news and ratings for VIR and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VIR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

VIR vs. The Competition

MetricVir BiotechnologyBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.08B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E Ratio-7.6026.5632.9627.39
Price / Sales23.9316.058.595.73
Price / CashN/A26.3721.9322.50
Price / Book1.834.074.403.70
Net Income-$437.99M-$22.86M$3.52B$392.17M
7 Day Performance-29.82%-7.26%-5.34%-4.53%
1 Month Performance-3.82%-4.96%-3.61%-5.86%
1 Year Performance70.16%-2.87%0.01%-7.78%

Vir Biotechnology Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
VIR
Vir Biotechnology
2.3718 of 5 stars
$9.58
-3.8%
$22.57
+135.6%
+76.9%$2.08B$68.56MN/A367
PRAX
Praxis Precision Medicines
2.918 of 5 stars
$332.97
+19.9%
$630.42
+89.3%
+76.0%$7.95B$8.55MN/A168
CYTK
Cytokinetics
3.066 of 5 stars
$55.14
+2.7%
$106.67
+93.4%
-15.5%$7.91B$88.04MN/A673
ABVX
Abivax
3.2658 of 5 stars
$87.00
+1.5%
$155.00
+78.2%
-20.7%$7.83BN/AN/A98
ALKS
Alkermes
2.5944 of 5 stars
$46.17
+0.6%
$55.06
+19.3%
+61.9%$7.71B$1.48B1,529.672,050

Related Companies and Tools


This page (NASDAQ:VIR) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners